Reviewer’s report

Title: A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain under medical practice conditions in Primary Care settings.

Version: 2 Date: 31 July 2010

Reviewer: gianluca bruti

Reviewer’s report:

The study by Navarro et al, performs the cost-effectiveness analysis of the pharmacological effects of pregabalin in the treatment of peripheral neuropathic pain.

The authors argued that the importance of this study consists on the fact that it has been performed in a “real clinical sample”.

I agree with the assumption of the authors that clinical trials are not completely representative of what happen in the “real world” and that we need of pharmacological studies able to obtained data more typical of what we observe in clinical practice.

Although this study represents an attempt to achieve these data, the current version of the paper has some shortcomings from both clinical, pharmacological and methodological point of view that have to be revised and clarified before publication.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

'I declare that I have no competing interests'